| Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection ML Faquetti, F Grisoni, P Schneider, G Schneider, AM Burden Scientific reports 12 (1), 7843, 2022 | 13 | 2022 |
| Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease ML Faquetti, L Slappendel, H Bigonne, F Grisoni, P Schneider, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 10 …, 2024 | 6 | 2024 |
| Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through … ML Faquetti, AMD la Torre, T Burkard, G Obozinski, AM Burden Pharmacoepidemiology and Drug Safety 32 (3), 366-381, 2023 | 5 | 2023 |
| JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort … ML Faquetti, E Vallejo-Yagüe, R Cordtz, L Dreyer, AM Burden PLoS One 18 (7), e0288757, 2023 | 2 | 2023 |
| Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care ML Faquetti, G Frey, D Stämpfli, S Weiler, AM Burden British Journal of Clinical Pharmacology 90 (6), 1376-1394, 2024 | 1 | 2024 |
| A data-driven approach to identify clusters of HbA1c longitudinal trajectories and associated outcomes in type 2 diabetes mellitus: a large population-based cohort study AMD la Torre, ML Faquetti, F Perez-Cruz, C Meier, S Weiler, AM Burden medRxiv, 2022.06. 14.22276398, 2022 | 1 | 2022 |
| Advancing Drug Utilisation and Drug Safety Research Through Interdisciplinary Methods ML Faquetti ETH Zurich, 2023 | | 2023 |
| Clustering of HBA1C longitudinal trajectories in type 2 diabetes mellitus (T2DM) D la Torre, A Martinez, MLMDS Faquetti, F Perez-Cruz, S Weiler, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 60-60, 2022 | | 2022 |
| Personalized prescribing in type 2 diabetes following the 2015 UK treatment guidelines: Description of non-insulin anti-diabetic drug (niad) utilization and polypharmacy patterns MLMDS Faquetti, D la Torre, A Martinez, T Burkard, A Burden PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 542-543, 2022 | | 2022 |
| Age and sex differences in polypharmacy patterns in new users of metformin: A UK-based descriptive study MLMDS Faquetti, T Burkard, D la Torre, A Martinez, A Burden PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 294-295, 2022 | | 2022 |
| POS0091 OFF-TARGET PROFILING OF JANUS KINASE (JAK) INHIBITORS IN RHEUMATOID ARTHRITIS: A COMPUTER-BASED APPROACH FOR DRUG SAFETY STUDIES AND REPURPOSING ML Faquetti, F Grisoni, P Schneider, G Schneider, AM Burden Annals of the Rheumatic Diseases 80 (Suppl 1), 255-255, 2021 | | 2021 |
